MONTREAL | Health Canada has approved Trisenox (arsenic trioxide) for relapsed or refractory acute promyelocytic leukemia (APL). This was made possible by a decision from Health Canada's Therapeutic Products Directorate to remove a prior regulatory prohibition on arsenic-containing drug therapies for use in humans and by granting priority review.
VANCOUVER | Providence Health Care and five of its Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) patients have launched a constitutional challenge to overturn a recent decision by the federal government preventing the delivery of life-saving treatment to vulnerable addictions patients.
